Current Edition

Recipharm to boost sterile liquids manufacturing capacity

The investment will support increased demand and help to secure new business at its Kaysersberg facility.

Global contract development and manufacturing organisation (CDMO), Recipharm, has announced a EUR 2.6 million investment for additional manufacturing capacity to support increased demand into its Kaysersberg facility.

This investment in the Kaysersberg facility, located in the Alsace region of France, will add additional capacity and capabilities for the company’s customers, as the company continues to secure new business for the future.

This latest investment is part of Recipharm’s phased expansion plan for the facility.

Recipharm in Kaysersberg is one of the company’s sterile manufacturing facilities, specialising in blow-fill-seal (BFS) technology for sterile liquids such as eye care and ear drops.

The site manufactures single-dose units and has an advanced aseptic process for sterile liquid packaging applications.

The facility has been inspected and approved by multiple regulatory agencies across the globe, including FDA.

The site is ISO 13485-certified (quality management system for medical devices), and holds a number of approvals for its environmental management systems and occupational health and safety management systems.